Raloxifene (Rix) effects on vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1) are not mediated by changes in steroid receptor (SR) co-repressors or co-activators or cell proliferation markers in a human endometrial cell line.

被引：0

|

作者：

Bocca, SM ^{[1
]}

Archer, DF ^{[1
]}

机构：

[1] Eastern Virginia Med Sch, Jones Inst Reprod Med, Norfolk, VA 23501 USA

来源：

FERTILITY AND STERILITY | 2005年 / 84卷

关键词：

D O I：

10.1016/j.fertnstert.2005.07.593

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

引用

收藏

页码：S230 / S230

页数：1

相关论文

共 3 条

[1] Raloxifene shows progestagenic effects on thrombospondin-1 (TSP-1) and down-regulation of progesterone receptors in a human endometrial cell line.
Bocca, SM
Archer, DF
[J]. FERTILITY AND STERILITY, 2005, 84 : S119 - S120
[2] SERUM THROMBOSPONDIN-1 (TSP-1), BASIC-FIBROBLAST GROWTH FACTOR (B-FGF), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR-2 (VEGFR-2) AS PREDICTIVE FACTORS FOR SORAFENIB PLUS INTERFERON-α2A (IFN) IN METASTATIC RENAL CELL CARCINOMA (MRCC): BIOLOGIC RESULTS FROM THE "RAPSODY'' RANDOMIZED PHASE II TRIAL
Bracarda, S.
Ludovini, V.
Porta, C.
Boni, C.
Santoro, A.
Gasparro, D.
Cortesi, E.
de Angelis, V.
Sisani, M.
Crino, L.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 284 - 284
[3] Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGM, VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial
Bracarda, S.
Ludovini, V.
Porta, C.
Boni, C.
Santoro, A.
Gasparro, D.
Cortesi, E.
De Angelis, V.
Sisani, M.
Crino, L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)